CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Adynxx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Adynxx Inc
100 Pine St Ste 500
Phone: (415) 512-7740p:415 512-7740 SAN FRANCISCO, CA  94111-5103  United States Ticker: ADYXADYX
This company ceased filing statements with the SEC on 3/20/2020.
Business Summary
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes-YesYes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Dennis G.Podlesak 66
Chief Executive Officer, Principal Financial Officer, Director RickOrr 5/3/2019 5/3/2019
Chief Scientific Officer, Director JulienMamet 5/3/2019 5/3/2019
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CHOICE THERAPEUTICS WRENTHAM MA US
Celleration, Inc. 6321 Bury Drive Eden Prairie MN United States
Alliqua Holdings, Inc. 1010 Stony Hill Road, Suite 200 Yareley PA United States

Business Names
Business Name
Adynxx Sub, Inc.
ADYX
Alliqua Holdings, Inc.
ALQA
Celleration, Inc.
CHOICE THERAPEUTICS

General Information
Number of Employees: 6 (As of 12/31/2018)
Outstanding Shares: 5,807,877 (As of 9/30/2019)
Shareholders: 5,005,211
Stock Exchange: OTC
Federal Tax Id: 582349413
Fax Number: (215) 702-8535


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 2, 2024